[Medical Treatments in Oncology 2023].


Journal

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
ISSN: 1724-5990
Titre abrégé: G Ital Nefrol
Pays: Italy
ID NLM: 9426434

Informations de publication

Date de publication:
03 Oct 2023
Historique:
medline: 28 11 2023
pubmed: 26 11 2023
entrez: 26 11 2023
Statut: epublish

Résumé

Medical Oncology since the beginning of the new millennium has recognized a great positive evolution in the care of cancer. In fact, for more than 60 years the two classical pillars of the antineoplastic therapy were hormone therapies mainly applied in breast, prostate and thyroid cancer, and chemotherapy seldom curative and heavily toxic. Nowadays some new treatments are available thanks to the advances in genomics, proteomics and molecular biology of tumor cells either to the advances in immunology studies. Specific pathways in cancer cells have been recognized and hit by targeted drugs. Monoclonal antibodies, tyrosine kinase inhibitors, checkpoint inhibitors, cellular therapies and vaccines are the new tools for oncologists. The last discovery is the antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic drugs. Unfortunately, these impressive advances have caused the appearance of new scientific, social, and financial problems. All these topics are discussed in the article.

Identifiants

pubmed: 38007823
pii: 40-s81-2023-04
pii:

Substances chimiques

Antineoplastic Agents 0
Antibodies, Monoclonal 0

Types de publication

English Abstract Journal Article Review

Langues

ita

Sous-ensembles de citation

IM

Informations de copyright

Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.

Auteurs

Alessandro Comandone (A)

SC Oncologia Medica - Ospedale San Giovanni Bosco, Torino; Gruppo Italiano Tumori Rari.

Antonella Boglione (A)

SC Oncologia Medica - Ospedale San Giovanni Bosco, Torino; Gruppo Italiano Tumori Rari.

Tiziana Comandone (T)

Scuola di Specializzazione in Farmacologia Ospedaliera- Università degli studi di Torino; Gruppo Italiano Tumori Rari.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH